ETF Managers Group’s Indaptus Therapeutics INDP Stock Holding History

ETF Managers Group’s Portfolio INDP Stock Details INDP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-148	Closed	-$72K	–	642
2020 Q1	$72K	Buy	148 +13	+10%	+$9.83K	﹤0.01%	523
2019 Q4	$145K	Buy	135 +108	+400%	+$149K	0.01%	527
2019 Q3	$46K	Buy	27 +4	+17%	+$11.9K	﹤0.01%	522
2019 Q2	$221K	Buy	23 +8	+53%	+$101K	0.01%	327
2019 Q1	$245K	Hold	15	–	–	0.01%	276
2018 Q4	$260K	Sell	15 -7	-32%	-$95.4K	0.01%	274
2018 Q3	$280K	Buy	+22	New	+$209K	0.01%	238
2018 Q2	–	Sell	-13	Closed	-$175K	–	544
2018 Q1	$175K	Buy	+13	New	+$184K	0.01%	229

Other funds holding INDP

MIH

Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return

IWC

Integrated Wealth Concepts Waltham, Massachusetts $20.5B AUM 24.45% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

ETF Managers Group's INDP Position: Q2 2020 in Review

ETF Managers Group sold out of Indaptus Therapeutics (INDP) in Q2 2020, closing a stake of 148 shares — an estimated $72K sold.

ETF Managers Group first reported a position in INDP in Q1 2018 and held it in 8 quarters. The position peaked at $280K in Q3 2018. 26 funds tracked by Wall St. Rank hold INDP as of Q2 2020.

ETF Managers Group reported no remaining Indaptus Therapeutics position as of Q2 2020 after selling out during the quarter.
ETF Managers Group sold 148 Indaptus Therapeutics shares in Q2 2020, an estimated $72K.
ETF Managers Group first reported a position in Indaptus Therapeutics in Q1 2018 and held it in 8 quarters.
ETF Managers Group's Indaptus Therapeutics position peaked at $280K in Q3 2018.
26 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q2 2020.

Based on ETF Managers Group's 13F filing for Q2 2020, filed 14 Aug 2020.